LifeSciences BC > News > Member Announcements

Print Friendly

DelMar Pharmaceuticals Announces $10 Million Registered Direct Offering Priced At-The-Market

September 20, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 20, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced that it entered into securities purchase agreements with certain institutional investors in connection with a registered direct offering, priced at-the-market, of an … Continue reading DelMar Pharmaceuticals Announces $10 Million Registered Direct Offering Priced At-The-Market

Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program

September 20, 2017
Arbutus Biopharma Corporation

Arbutus’ LNP Technology Further Validated with New Results Arbutus to Receive Single Digit Royalties on Sales of Patisiran VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 20, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, announced today that the Company’s lipid nanoparticle (LNP) licensee Alnylam Pharmaceuticals, Inc. … Continue reading Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

September 20, 2017
DelMar Pharmaceuticals, Inc.

Newly issued patent claims provide patent protection into 2033 VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 20, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United … Continue reading DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference

September 18, 2017
Aquinox Pharmaceuticals, Inc.

VANCOUVER, British Columbia, Sept. 18, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (Aquinox) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming 2017 Cantor Fitzgerald Global Healthcare Conference in New … Continue reading Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

September 18, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia, and MENLO PARK, Calif., Sept. 18, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug … Continue reading DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

Aspect Biosystems Partners with InSCREENeX and Fraunhofer ITEM

September 14, 2017
Aspect Biosystems Ltd.

A Canada-Germany partnership to develop game-changing bioprinted models of tissue contraction. Vancouver, BC, Canada – September 13, 2017 – Aspect Biosystems Ltd., a leader in the field of 3D bioprinting and tissue engineering, is pleased to announce an international research collaboration with InSCREENeX GmbH (Braunschweig, Germany) and Fraunhofer ITEM (Institute for Toxicology and Experimental Medicine, … Continue reading Aspect Biosystems Partners with InSCREENeX and Fraunhofer ITEM

BIOLUX TO EXHIBIT ORTHOPULSE® AT UPCOMING TRADE-SHOWS IN NORTH AMERICA AND EUROPE

September 14, 2017
Biolux Research

VANCOUVER, CANADA / September 14, 2017 – Biolux Research is pleased to announce that it will be exhibiting OrthoPulse® at trade-shows and meetings in North America and Europe this fall: September 14-16, 2017 Canadian Association of Orthodontics (CAO) 69th Annual Scientific Session Toronto, Canada September 14-17, 2017 Great Lakes Association of Orthodontists GLAO/MSO/SWSO Annual Session … Continue reading BIOLUX TO EXHIBIT ORTHOPULSE® AT UPCOMING TRADE-SHOWS IN NORTH AMERICA AND EUROPE

RepliCel’s Partnership Initiatives Mature into Licensing Negotiations

September 13, 2017
RepliCel Life Sciences Inc.

Due diligence and confidential discussions now moving into negotiations for products in both the tendon repair and aesthetics franchises VANCOUVER, BC  September 13, 2017 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (RepliCel or the Company), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it anticipates maturing … Continue reading RepliCel’s Partnership Initiatives Mature into Licensing Negotiations

AbCellera Launches Antibody Discovery Collaboration with GSK

September 12, 2017
AbCellera Biologics Inc.

AbCellera announces the initiation of a collaboration with GSK for the discovery of monoclonal antibodies against an undisclosed membrane protein target.   Vancouver, Canada (September 12, 2017) AbCellera Biologics, Inc. today announced that it has entered into an antibody discovery research collaboration with GSK, whereby AbCellera will apply its high-throughput single-cell antibody screening platform to … Continue reading AbCellera Launches Antibody Discovery Collaboration with GSK

DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme

September 12, 2017
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 11, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the development of new cancer therapies, today announced the initiation of a Phase 2 clinical trial for its lead agent VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The biomarker-driven clinical … Continue reading DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme